[Sensitivity of BALB/c and WR strain mice to the immunodepressive action of cyclophosphamide and thiophosphamide]. 1984

K N Ir, and L Iu Telegin, and L A Pevnitskiĭ, and A M Malashenko

Experiments were made on BALB/cJ YSto and WR/Y mice to study the immunosuppressant action of cyclophosphamide (CP) and thiophosphamide (thiotepa) in vivo. WR mice were found to be significantly more sensitive to the immunosuppressant action of thiotepa than BALB/c mice and to have similar sensitivity to the action of CP. BALB/c mice appeared highly resistant to the action of both the drugs. Based on the data obtained and those reported in the literature a possible parallelism is suggested between the mutagenic and immunosuppressant action of CP and thiotepa.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008815 Mice, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation. Inbred Mouse Strains,Inbred Strain of Mice,Inbred Strain of Mouse,Inbred Strains of Mice,Mouse, Inbred Strain,Inbred Mouse Strain,Mouse Inbred Strain,Mouse Inbred Strains,Mouse Strain, Inbred,Mouse Strains, Inbred,Strain, Inbred Mouse,Strains, Inbred Mouse
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004306 Dose-Response Relationship, Immunologic A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell. Immunologic Dose-Response Relationship,Relationship, Immunologic Dose-Response,Dose Response Relationship, Immunologic,Dose-Response Relationships, Immunologic,Immunologic Dose Response Relationship,Immunologic Dose-Response Relationships,Relationship, Immunologic Dose Response,Relationships, Immunologic Dose-Response
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000921 Antibody-Producing Cells Cells of the lymphoid series that can react with antigen to produce specific cell products called antibodies. Various cell subpopulations, often B-lymphocytes, can be defined, based on the different classes of immunoglobulins that they synthesize. Antibody-Producing Cell,Antibody-Secreting Cell,Antibody-Secreting Cells,Immunoglobulin-Producing Cells,Immunoglobulin-Secreting Cells,Antibody Producing Cell,Antibody Producing Cells,Antibody Secreting Cell,Antibody Secreting Cells,Cell, Antibody-Producing,Cell, Antibody-Secreting,Cell, Immunoglobulin-Producing,Cell, Immunoglobulin-Secreting,Cells, Antibody-Producing,Cells, Antibody-Secreting,Cells, Immunoglobulin-Producing,Cells, Immunoglobulin-Secreting,Immunoglobulin Producing Cells,Immunoglobulin Secreting Cells,Immunoglobulin-Producing Cell,Immunoglobulin-Secreting Cell
D013045 Species Specificity The restriction of a characteristic behavior, anatomical structure or physical system, such as immune response; metabolic response, or gene or gene variant to the members of one species. It refers to that property which differentiates one species from another but it is also used for phylogenetic levels higher or lower than the species. Species Specificities,Specificities, Species,Specificity, Species
D013852 Thiotepa A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed). Thio-Tepa,Thiophosphamide,Triethylenethiophosphoramide,AI3-24916,Girostan,NSC-6396,Tespa,Tespamin,Tris(1-aziridinyl)phosphine Sulfide,AI3 24916,AI324916,NSC 6396,NSC6396,Thio Tepa

Related Publications

K N Ir, and L Iu Telegin, and L A Pevnitskiĭ, and A M Malashenko
March 1979, Biulleten' eksperimental'noi biologii i meditsiny,
K N Ir, and L Iu Telegin, and L A Pevnitskiĭ, and A M Malashenko
May 2009, Neuroreport,
K N Ir, and L Iu Telegin, and L A Pevnitskiĭ, and A M Malashenko
April 1983, Biulleten' eksperimental'noi biologii i meditsiny,
K N Ir, and L Iu Telegin, and L A Pevnitskiĭ, and A M Malashenko
January 1982, Acta radiologica. Oncology,
K N Ir, and L Iu Telegin, and L A Pevnitskiĭ, and A M Malashenko
May 1991, Contact dermatitis,
K N Ir, and L Iu Telegin, and L A Pevnitskiĭ, and A M Malashenko
January 2022, Evidence-based complementary and alternative medicine : eCAM,
K N Ir, and L Iu Telegin, and L A Pevnitskiĭ, and A M Malashenko
October 1991, Jikken dobutsu. Experimental animals,
K N Ir, and L Iu Telegin, and L A Pevnitskiĭ, and A M Malashenko
February 1983, The Australian journal of experimental biology and medical science,
K N Ir, and L Iu Telegin, and L A Pevnitskiĭ, and A M Malashenko
July 2019, International immunopharmacology,
K N Ir, and L Iu Telegin, and L A Pevnitskiĭ, and A M Malashenko
March 1973, Antibiotiki,
Copied contents to your clipboard!